# US 2016/0354314 A1 · Process for preparing carrier particles for dry powders for inhalation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354314 A1
- Document ID: US20160354314A1
- Status: Published application
- Kind: A1
- Application number: 15/241,516
- Filed: 2016-08-19
- Published: 2016-12-08
- Earliest claimed: 2010-04-01
- Assignees: Chiesi Farmaceutici S.p.A.
- Applicants: CHIESI FARMACEUTICI S.p.A.
- Inventors: Rossella MUSA; Daniela COCCONI; Alain CHAMAYOU; Laurence GALET
- Web page: https://patentgrep.com/patent/US20160354314A1

## CPC

- A61K 9/1682: {Processes}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/145: {with organic compounds}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.

## Claims

### Claim 1

A process for the preparation of a carrier for powder pharmaceutical compositions for inhalation,
said process comprising dry coating lactose particles having a mass diameter of 30 to 1000 microns with 0.1 to 1.3% by weight, based on the weight of the carrier, of magnesium stearate, to obtain lactose particles surface coated with said magnesium stearate in an extent of more than 60% of the surface of said lactose particles,
wherein said dry coating is carried out in a high shear mixer granulator based on friction behavior at a rotation speed equal of 500 r.p.m. to 2500 r.p.m.

### Claim 2 (depends on 1)

A process according to claim 1, wherein said high shear mixer granulator is the CYCLOMIX™ apparatus.

### Claim 3 (depends on 1)

A process according to claim 1, wherein said rotation speed is 1000 to 2000 r.p.m.

### Claim 4 (depends on 2)

A process according to claim 2, wherein said rotation speed is 1000 to 2000 r.p.m.

### Claim 5 (depends on 1)

A process according to claim 1, wherein said dry coating step is carried out for a time of 2 to 20 minutes.

### Claim 6 (depends on 1)

A process according to claim 1, wherein said dry coating step is carried out for a time of 5 to 15 minutes.

### Claim 7 (depends on 1)

A process according to claim 1, wherein at least 80% of the surface of said lactose particles is coated with said magnesium stearate.

### Claim 8 (depends on 1)

A process according to claim 1, wherein at least 90% of the surface of said lactose particles is coated with said magnesium stearate.

### Claim 9 (depends on 1)

Carrier particles for a dry powder pharmaceutical formulation, which are prepared by a process according to claim 1.

### Claim 10 (depends on 9)

Carrier particles according to claim 9, wherein said rotation speed is 1000 to 2000 r.p.m.

### Claim 11 (depends on 9)

A pharmaceutical composition in the form of a dry powder for inhalation, comprising carrier particles according to claim 9 and one or more active ingredients.

### Claim 12 (depends on 11)

A pharmaceutical composition according to claim 11, wherein said active ingredient comprises at least one beta2-agonist selected from the group consisting of salmeterol, formoterol, milveterol, vilanterol, olodaterol, indacaterol, a salt thereof, and a solvate form thereof.

### Claim 13 (depends on 11)

A pharmaceutical composition according to claim 11, wherein said active ingredient comprises at least one anticholinergic selected from the group consisting of tiotropium bromide, ipratropium bromide, oxitropium bromide, oxybutynin chloride, aclidinium bromide, trospium chloride, glycopyrronium bromide, GSK 573719, and GSK 1160274.

### Claim 14 (depends on 11)

A pharmaceutical composition according claim 11, wherein said active ingredient comprises at least one corticosteroid selected from the group consisting of beclomethasone dipropionate, fluticasone propionate, fluticasone furoate, budesonide, and mometasone furoate.

### Claim 15 (depends on 11)

A pharmaceutical composition according to claim 11, wherein said active ingredient comprises a phosphodiesterase-inhibitor.

### Claim 16 (depends on 11)

A dry powder inhaler, containing a pharmaceutical composition according to claim 11.

### Claim 17 (depends on 11)

A method for the prevention and/or treatment of a respiratory, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 11.

### Claim 18 (depends on 17)

A method according to claim 17, wherein said respiratory conditions is asthma, chronic obstructive pulmonary disease, or allergic rhinitis.
